Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:CELU NASDAQ:CTMX NASDAQ:INBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.08-5.4%$2.98$1.05▼$3.97$345.37M1.92714,182 shs261,995 shsCELUCelularity$3.94+2.3%$2.92$1.00▼$5.22$94.36M0.7966,027 shs58,298 shsCTMXCytomX Therapeutics$2.04-0.5%$2.25$0.40▼$3.10$336.42M2.133.92 million shs1.21 million shsINBXInhibrx Biosciences$28.20+1.1%$21.50$10.81▼$28.29$408.48M0.24106,458 shs77,071 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics0.00%-2.84%+10.81%-0.81%+4.95%CELUCelularity0.00%+3.96%+20.12%+79.91%+36.81%CTMXCytomX Therapeutics0.00%-3.77%-6.85%-19.05%+75.86%INBXInhibrx Biosciences0.00%+12.80%+28.65%+107.96%+102.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics1.3124 of 5 stars3.51.00.00.00.60.80.6CELUCelularity0.5745 of 5 stars2.01.00.00.01.71.70.0CTMXCytomX Therapeutics4.2237 of 5 stars3.51.00.04.73.31.71.3INBXInhibrx Biosciences1.5809 of 5 stars0.03.00.04.62.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75152.03% UpsideCELUCelularity 0.00N/A$6.0052.28% UpsideCTMXCytomX Therapeutics 3.00Buy$5.75181.86% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest CELU, INBX, ADCT, and CTMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform8/18/2025CELUCelularityWBB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageModerate Buy$6.008/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.007/31/2025CTMXCytomX TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.006/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.006/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $10.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M4.88N/AN/A($1.77) per share-1.74CELUCelularity$54.22M1.74N/AN/A$0.37 per share10.65CTMXCytomX Therapeutics$141.10M2.38$0.36 per share5.64$0.73 per share2.79INBXInhibrx Biosciences$200K2,041.68$117.50 per share0.24$4.73 per share5.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.57N/AN/AN/A-220.00%N/A-53.73%11/6/2025 (Estimated)CELUCelularity-$57.89M-$2.65N/A∞N/A-106.77%-271.88%-42.82%11/5/2025 (Estimated)CTMXCytomX Therapeutics$31.87M$0.563.64N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)INBXInhibrx Biosciences$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)Latest CELU, INBX, ADCT, and CTMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/29/2025Q1 2025CELUCelularityN/A-$1.02N/A-$1.02N/A$5.74 million8/13/2025Q2 2025INBXInhibrx Biosciences-$2.92-$1.85+$1.07-$1.85N/A$1.30 million8/12/2025Q2 2025ADCTADC Therapeutics-$0.36-$0.50-$0.14-$0.50$17.82 million$18.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.934.66CELUCelularity4.070.380.28CTMXCytomX TherapeuticsN/A4.204.20INBXInhibrx Biosciences1.454.984.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%CELUCelularity19.02%CTMXCytomX Therapeutics67.77%INBXInhibrx Biosciences82.46%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%CELUCelularity22.10%CTMXCytomX Therapeutics6.60%INBXInhibrx Biosciences17.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310112.50 million106.42 millionOptionableCELUCelularity22023.95 million18.66 millionOptionableCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableINBXInhibrx Biosciences16614.48 million12.01 millionOptionableCELU, INBX, ADCT, and CTMX HeadlinesRecent News About These CompaniesGroupe la Francaise Purchases New Position in Inhibrx Biosciences, Inc. $INBXAugust 27, 2025 | marketbeat.comInhibrx Biosciences Reports Q2 2025 Financial ResultsAugust 26, 2025 | tipranks.comInhibrx Biosciences (NASDAQ:INBX) Receives Market Perform Rating from JMP SecuritiesAugust 25, 2025 | americanbankingnews.comInhibrx Biosciences' (INBX) "Market Perform" Rating Reiterated at JMP SecuritiesAugust 24, 2025 | marketbeat.comHighTower Advisors LLC Acquires 90,002 Shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX)August 19, 2025 | marketbeat.comInhibrx Biosciences (NASDAQ:INBX) Upgraded by Wall Street Zen to Hold RatingAugust 18, 2025 | marketbeat.comInhibrx Biosciences (NASDAQ:INBX) Releases Earnings Results, Beats Estimates By $1.07 EPSAugust 15, 2025 | marketbeat.comInhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deXTX Topco Ltd Makes New Investment in Inhibrx Biosciences, Inc. (NASDAQ:INBX)August 14, 2025 | marketbeat.comInhibrx Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | prnewswire.comInhibrx Biosciences (INBX) Projected to Post Earnings on TuesdayAugust 6, 2025 | marketbeat.comInhibrx Biosciences Advances HexAgon-HN Study for Head, Neck CancerJuly 29, 2025 | msn.comInhibrx Biosciences: Seeing Soon If The Momentum Is Just HypeJuly 18, 2025 | seekingalpha.comNoteworthy Tuesday Option Activity: INBX, ODP, AZO | NasdaqJuly 10, 2025 | nasdaq.comINBX - Inhibrx Biosciences Inc Executives - MorningstarJuly 2, 2025 | morningstar.comMInhibrx Biosciences, Inc. (INBX) - Yahoo FinanceJune 28, 2025 | finance.yahoo.comInhibrx Biosciences Inc (INBX) - Investing.comJune 25, 2025 | investing.comInhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deInhibrx Reports First Quarter 2025 Financial ResultsMay 14, 2025 | prnewswire.comInhibrx Biosciences reshuffles leadership, appoints new CSO and PresidentApril 3, 2025 | investing.comInhibrx announces leadership changes as co-founder departsApril 2, 2025 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELU, INBX, ADCT, and CTMX Company DescriptionsADC Therapeutics NYSE:ADCT$3.08 -0.18 (-5.38%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$3.16 +0.09 (+2.76%) As of 08/29/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Celularity NASDAQ:CELU$3.94 +0.09 (+2.34%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$3.76 -0.18 (-4.44%) As of 08/29/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.CytomX Therapeutics NASDAQ:CTMX$2.04 -0.01 (-0.49%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.05 +0.01 (+0.54%) As of 08/29/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Inhibrx Biosciences NASDAQ:INBX$28.20 +0.32 (+1.15%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$28.19 -0.01 (-0.04%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
